TROPION-Breast03: assessing Dato-DXd with a PD-1 inhibitor: The outcomes of these trials, expected to be obtained in the future, will provide further insights into the potential benefits of combining ADCs with various immunotherapies, including PD-1 inhibitors and CD47 inhibitors, in the treatment of breast cancer. Here, CD47 is linked to breast cancer.